Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
Processa Pharmaceuticals (NASDAQ: PCSA) will host a conference call on March 25, 2021, at 5:30 p.m. ET to discuss its fourth quarter 2020 results and clinical pipeline updates. Investors can join the call via a toll-free number or through a live webcast. Processa focuses on developing products for patients with unmet medical needs, with programs targeting cancers and gastrointestinal disorders. The company highlights its experienced development team, which has been involved with over 30 FDA drug approvals.
- Active clinical pipeline includes programs for metastatic colorectal cancer and breast cancer.
- Experienced development team with over 30 FDA drug approvals, enhancing credibility.
- None.
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announces it will host a conference call and live webcast on March 25, 2021, at 5:30 p.m. Eastern time to discuss its fourth quarter 2020 results and provide an update on the Company’s clinical pipeline.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Date: March 25, 2021
Time: 5:30 p.m. ET
Toll Free: 877-545-0320; Entry Code: 805295
International: 973-528-0016; Entry Code: 805295
Live Webcast: https://www.webcaster4.com/Webcast/Page/2572/40452
Conference Call Replay Information
Toll-free: 877-481-4010
International: 919-882-2331
Replay Passcode: 40452
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com .
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com
FAQ
When is the Processa Pharmaceuticals conference call scheduled?
How can I participate in the Processa Pharmaceuticals conference call?
What is the focus of the upcoming Processa Pharmaceuticals conference call?
What are the main clinical programs discussed by Processa Pharmaceuticals?
What type of company is Processa Pharmaceuticals?
